FLT1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human Burkitt lymphoma B lymphoblast cell line. This product features targeted disruption of the FLT1 gene, which encodes the vascular endothelial growth factor receptor 1 (VEGFR-1). The polyclonal format provides a heterogeneous pool of knockout cells, enabling robust loss-of-function studies without the selection of single-cell clones.
The Raji host cell line is an EBV-positive B lymphoblast model established from an 11-year-old male with Burkitt lymphoma. These cells retain characteristic features of malignant B lymphocytes and are widely employed as a model system for B-cell malignancies, including studies of lymphomagenesis, viral oncogenesis, and immune cell signaling. The well-characterized genetic and phenotypic background of Raji cells makes them a valuable platform for investigating gene function in a hematological cancer context.
FLT1 (VEGFR-1) is a high-affinity receptor tyrosine kinase for VEGFA, VEGFB, and placental growth factor (PGF). Ligand binding activates multiple downstream signaling cascades, including PI3K-AKT and MAPK/ERK pathways, mediated through interactions with KDR (VEGFR-2), Neuropilin-1, and SH2 domain-containing adaptor proteins. Key downstream effectors include PLCG1, eNOS, and the transcription factors FOS and JUN. The expression of FLT1 is transcriptionally regulated by HIF1A under hypoxic conditions and by estrogen, placing it at the nexus of angiogenic, survival, and migratory signaling networks.
In the Raji lymphoma context, disruption of FLT1 eliminates VEGFR-1 surface expression, thereby abrogating ligand-induced activation of PI3K-AKT and MAPK/ERK signaling. This loss-of-function model can be used to interrogate VEGF-dependent survival, proliferation, and crosstalk with the tumor microenvironment. Given the emerging roles of VEGF signaling in B-cell malignancies, the polyclonal knockout population provides a versatile tool for dissecting autocrine and paracrine VEGF effects on lymphoma cell behavior without clonal bias.
This knockout cell product is suited for a broad range of research applications, including VEGFR1 signaling studies, angiogenesis research, tumor microenvironment analysis, and preeclampsia modeling. Researchers can employ endpoint assays such as Western blotting for FLT1 and phospho-AKT/ERK, RT-qPCR, flow cytometry for receptor detection, RNA-seq transcriptomics, proliferation and apoptosis assays, VEGF ligand binding assays, transwell migration, and co-culture angiogenesis models. The system also supports drug target validation and testing of anti-VEGF therapeutics. For further information, please contact Ascent Research.
